



Global Corporate Headquarters
7 Argent Place, Ringwood
Victoria 3134, Australia
Tel: +61 (0) 3 9837 4200
www.trajanscimed.com

Trajan Group Holdings Limited
ACN 152 617 706

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

ASX RELEASE

Trajan announces the successful completion of a \$29.7 million institutional placement

Highlights

- Successful completion of a fully underwritten institutional placement (**Placement**) of approximately 14.8 million shares to raise ~\$29.7 million
- The Placement was priced at \$2.00 per share (**Offer Price**) and was well supported by new and existing institutional and sophisticated investors from Australia and overseas
- Proceeds of the Placement will be applied to partially fund the acquisition of Chromatography Research Supplies, Inc
- Non-underwritten Share Purchase Plan raising up to \$5.0 million to open on Friday 24 June 2022

20 June 2022 - Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (**Trajan**) has today announced the successful completion of a fully underwritten \$29.7 million institutional placement to partially fund the acquisition of Chromatography Research Supplies, Inc (**CRS**).

Commenting on the equity raising, CEO and Managing Director, Stephen Tomisich said: "We are very pleased with the strong support provided by existing and new shareholders which highlights the compelling fundamentals of this exciting acquisition opportunity. Through completing the acquisition of CRS, we can further enhance our global reach in providing best in class products along the analytical workflow."

"This acquisition enhances and extends our production capabilities to service our expanding gas chromatography business, including in the critical area of the gas chromatography inlet and sample introduction and the ability to offer end-to-end product solutions for our customers."

Placement Details:

Trajan has completed the capital raising via a Placement of new, fully paid ordinary shares (**New Shares**) to raise approximately \$29.7 million before costs.

The proceeds from the Placement will be used to partially fund the acquisition of CRS, a leading global manufacturer of high-quality analytical consumables based in Kentucky, USA.

The Placement of approximately 14.8 million New Shares at an Offer Price of \$2.00 was made to sophisticated and institutional investors and utilises Trajan's available Placement capacity under ASX listing rule 7.1.

The Offer Price of \$2.00 per New Share represents a 11.1% discount to the last close price of \$2.25 as at 16 June 2022.

Canaccord Genuity (Australia) Limited and Ord Minnett Limited acted as joint lead managers and underwriters to the Placement and DLA Piper is the legal advisor to Trajan.

Trajan expects ASX to lift the trading halt of its shares today.



NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

Share Purchase Plan

In addition to the Placement, Trajan aims to raise up to \$5.0 million via a Share Purchase Plan (**SPP**). The SPP will enable Trajan shareholders as at the record date of 7.00pm (AEST) on 16 June 2022 with a registered address in Australia or New Zealand (**Eligible Shareholders**) to have the opportunity to apply for New Shares at the same price as the Placement, being \$2.00 per New Share. Eligible Shareholders will be offered the opportunity under the SPP to apply for up to \$30,000 worth of New Shares. Trajan retains the right to accept oversubscriptions or to scale back applications (in whole or in part) at its absolute discretion (subject to the ASX Listing Rules).

Participation in the SPP by Eligible Shareholders is entirely optional. The SPP is not underwritten.

New Shares issued under the SPP will rank equally with existing fully paid ordinary shares in Trajan then on issue.

The terms and conditions of the SPP will be detailed in an SPP Offer Booklet, expected to be dispatched to Eligible Shareholders and released to the ASX on 24 June 2022. Eligible Shareholders should review the SPP Offer Booklet in full before deciding whether or not to participate in the SPP.

Key Dates

Event	Date ¹
SPP Record Date	7:00pm, Thursday, 16 June 2022
Settlement of New Securities under the Placement (DvP)	Wednesday, 22 June 2022
Allotment and normal trading of New Securities issued under the Placement	Thursday, 23 June 2022
SPP opens	Friday, 24 June 2022
SPP closes	5:00pm, Tuesday, 12 July 2022
SPP results announced to the ASX	Friday, 15 July 2022
SPP Securities issued	Tuesday, 19 July 2022

Further Information

Further details on the Placement are set out in the Investor Presentation (**Trajan Capital Raising Presentation**) lodged on the ASX on 17 June 2022. The Investor Presentation contains important information including key risks and foreign offer restrictions with respect to the Placement. For other questions, you should consult your broker, solicitor, accountant, tax adviser, financial adviser, or other professional adviser.

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited.

END

¹ The above timetable is indicative only and is subject to change without notice. All dates and times are Australian Eastern Standard Time (AEST).



NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

Contact:

Investors

Rebecca Wilson
WE Communications
investorrelations@trajanscimed.com

Media

Amy Miller
WE Communications
amymi@we-worldwide.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of 600 people with seven manufacturing sites across the US, Australia, Europe, and Malaysia, and operations in Australia, the US, Asia, and Europe.

Important Notice

Not for distribution or release in the United States

This announcement may not be distributed or released in the United States. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold under the Offer and have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, to any person in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.

Forward-looking statements

The information in this announcement is subject to change without notice and Trajan is not obliged to update or correct it. This presentation contains statements that constitute "forward-looking statements". The forward-looking statements include statements regarding Trajan's intent, belief, or current expectations with respect to the timetable, conduct, and outcome of the Offer and the use of proceeds. This includes statements about the plans, objectives, and strategies of the management of Trajan, statements about the industry and markets in which Trajan operates, statements about the future performance of Trajan's business and its financial condition, indicative drivers, forecasted economic indicators, and the outcome of the Offer and the use of proceeds. Words such as "will", "may", "expect", "indicative", "intent", "seek", "would", "should", "could", "continue", "plan", "probability", "risk", "forecast", "likely", "estimate", "anticipate", "believe", "aim" or similar words are used to identify forward-looking statements.

You are strongly cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions, and estimates in this presentation speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this announcement are not indications, guarantees, or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Trajan, its officers, employees, agents, and advisers, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

There can be no assurance that actual outcomes will not differ materially from these statements. Several important factors could cause actual results or performance to differ materially from the forward-looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of COVID-19, the Australian and global economic environment and capital market conditions, and other risk factors set out in this announcement. Investors should consider the forward-looking statements contained in this presentation in light of those risks and disclosures. The forward-looking statements are based on information available to Trajan as at the date of this presentation.

To the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements whether as a result of new information, future events or results, or otherwise is disclaimed. Trajan disclaims any responsibility to update or revise any forward-looking statement to reflect any change in Trajan's financial condition, status or affairs, or any change in the events, conditions, or circumstances on which a statement is based, except as required by law.